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Abstract
Effective chemical compound toxicity screening is of paramount importance for safe cardiac drug development. Using
mammals in preliminary screening for detection of cardiac dysfunction by electrocardiography (ECG) is costly and requires
a large number of animals. Alternatively, zebrafish embryos can be used as the ECG waveform is similar to mammals,
a minimal amount of chemical is necessary for drug testing, while embryos are abundant, inexpensive and represent
replacement in animal research with reduced bioethical concerns. We demonstrate here the utility of pre-feeding stage
zebrafish larvae in detection of cardiac dysfunction by electrocardiography. We have optimised an ECG recording system by
addressing key parameters such as the form of immobilization, recording temperature, electrode positioning and
developmental age. Furthermore, analysis of 3 days post fertilization (dpf) zebrafish embryos treated with known QT
prolonging drugs such as terfenadine, verapamil and haloperidol led to reproducible detection of QT prolongation as
previously shown for adult zebrafish. In addition, calculation of Z-factor scores revealed that the assay was sensitive and
specific enough to detect large drug-induced changes in QTc intervals. Thus, the ECG recording system is a useful drug-
screening tool to detect alteration to cardiac cycle components and secondary effects such as heart block and arrhythmias
in zebrafish larvae before free feeding stage, and thus provides a suitable replacement for mammalian experimentation.
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Introduction
Repolarisation abnormalities can lead to various conditions,
such as cardiac arrhythmias and QT prolongation (where the
duration of ventricular depolarisation and repolarisation is
extended). Repolarisation in human ventricles occurs mainly via
the voltage-gated potassium channel (hERG) in phase 3 of the
ventricular myocyte action potential [1]. Therefore, disruption to
this ion channel can result in QT prolongation, which is often
a predisposing factor to arrhythmias and can be monitored
through electrophysiological recordings. The cause of QT pro-
longation may be genetic (e.g. long QT syndrome) or drug-
induced (e.g. anti-histamine terfenadine) and can lead to the
development of tachycardia (Torsade de Pointes; [1]). Cardiac
arrhythmias originate from abnormal electrical activity in the
heart and may be life-threatening (leading to sudden cardiac
arrest) or merely irritating (palpitations). Particularly, arrhythmias
resulting from drug overdose can be fatal if left untreated, with
sudden cardiac deaths accounting for approximately 450,000
deaths in the USA every year [2]. However, the mechanisms of
many arrhythmias in the clinical setting remain poorly understood
[3]. QT prolongation has received greater regulatory attention in
recent years and there is a growing demand to find ways to
counteract this problem using novel screens [4] [5]. Particularly,
drug-induced QT prolongation is a growing problem and accounts
for around 20% of failures in the drug development process, as it
can be caused by many compounds that are often unrelated to
each other in structure and function. Additionally, it can also
occur by various mechanisms, such as blocking of cardiac ion
channels such (e.g. hERG), either when they are inactive/active or
open/closed [6]. Many compounds like terfenadine were only
found to be QT prolonging post-marketing, as the old drug
development standards were not able to detect confounding
factors [7]. Therefore, pharmaceutical companies and regulatory
agencies addressed this problem by developing in silico models and
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by introducing new standards in the drug development program
[8].
Repolarisation of the myocardium is complex with several ion
channels and various other components, such as cytoskeletal
elements and receptors, playing an important role. This makes it
difficult to identify the specific components that are affected by
either drugs or genetic defects, which has raised the importance of
zebrafish as a suitable model due to its electrophysiological
similarity to humans [9]. The characteristics of cardiac myocyte
action potentials from zebrafish closely resemble those of human
myocytes, as orthologues of the cardiac ion channels found in
humans exist in zebrafish, e.g. zERG (orthologue of human
hERG) [10]. Although the zebrafish heart is two-chambered, it
does have a coronary vasculature with the heart rate (120–
180 bpm) and QT intervals (400–500 ms) similar to those
observed in humans, whereas in mice the heart rate is much
higher (300–600 bpm) and QT intervals are shorter (50 ms) [11]
[12].
Zebrafish heart development occurs very rapidly, already
beating 24 hours post-fertilisation, thus cardiac activity can be
assessed relatively early compared to other animal models [13]
[14]. Zebrafish produce a high number of rapidly developing
embryos and therefore provide an ideal in vivo model for genetic,
pharmacological and toxicological high throughput (HT) verte-
brate screens [15] [16]. A number of reports describe HT
screening of compounds demonstrating the potential of zebrafish
in such assays [17] [18]. Using zebrafish embryos (referred to here
as 0–5 dpf (days post fertilisation)) has several advantages for
specifically detecting drug effects on the heart: 1) small incubation
volume is needed; 2) animals can be kept alive for days without
changing the solution, allowing relatively long-term studies; 3)
diffusion of chemicals can occur through the skin; 4) embryos are
not regulated under the UK Scientific Procedure Act 1986 and
European Directive 2010/63/EU, and thus carry reduced bio-
ethical limitations. Importantly, as zebrafish have similar electrical
properties to the mammalian heart and appear to respond very
similarly to drug treatment as humans [2] [16], they have been
proposed as a useful model for drug toxicity testing [16] [19][20].
Recently, cardiac repolarisation was used as a phenotypic readout
in a drug-sensitised zebrafish screen for repolarisation genes [21],
however this was restricted to manual measurement of action
potential duration without an attempt at scaling up the electro-
physiology technology.
Measuring the electrocardiogram of zebrafish embryos (5 dpf)
using a single glass electrode has been demonstrated [20] and
applied to recording ECGs in zebrafish larvae (7 dpf) following
drug treatment with QRS prolonging agents [22]. An adult
zebrafish ECG recording system has also been established and
been shown to be useful to screen for QT prolongation, cardiac
injury and heart regeneration [2] [19][23]. An in vitro ECG
method [24] and a flexible microelectrode array ECG system [25]
have also been recently developed. However, all these methods
have been developed for adult fish or late stage larvae that are
subjected to animal experimentation licencing, and therefore incur
regulatory restrictions in their use.
For embryos and pre free-feeding stage larvae, the high
throughput methods developed thus far have been limited to
detecting the heartbeat in zebrafish embryos using video recording
[26] [27] and optical mapping [28]. One recent method developed
was the visualisation of voltage dynamics in the zebrafish heart
[29], which was able to detect cardiac dysfunction following
application of the QT prolonging drug astemizole on 3 dpf
embryos. However, as with video recording this method lacks the
temporal and dynamic resolution required for analysis of
components within the cardiac cycle that can be obtained by
ECG, and thus is limited in data collection and utility of analysis.
Taken together, while proof of principle ECG detection in
embryonic and early stage larval zebrafish has been demonstrated,
a robust method suitable for drug screening purposes is lacking.
Therefore, we have optimised a method of ECG detection in early
stage zebrafish larvae and demonstrated its utility in detecting the
specific effect of QT prolonging and other cardiotoxic drugs.
Materials and Methods
Zebrafish Maintenance and Embryo Collection
Wild-type AB* zebrafish were maintained using standard
conditions according to the UK Animals (Scientific Procedures)
Act of 1986 in a flow-through system of aerated, charcoal filtered
tap water with a 12 hour light/dark cycle (Tecniplast; UK).
Breeding pairs were set up in breeding cages the day before
collection of embryos. Embryos were obtained from crosses the
following morning and then transferred immediately to E3 embryo
medium (Sigma Aldrich), which was changed daily and main-
tained at 28uC.
ECG Recording Procedure
For all experiments, except the anaesthetic and tubocurarine
experiments, fish larvae were anaesthetised in ethyl-3 amino-
benzoate methanesulfonate (0.3 mg/ml; Sigma) for 5–10 mins
before transfer into 3 ml of embryo medium in the plate used for
subsequent measurements. Once anaesthetised, one embryo was
then transferred to the ECG recording plate (mini Petri dish with
an unscented paraffin wax surface, containing 3 ml of fresh E3
embryo medium without MESAB). The embryo was positioned
ventrally within a groove in the wax, and the tip (2 mm diameter)
of a filled pre-pulled borosilicate glass micropipette (P84, World
Precision Instruments) was positioned on the skin surface between
the ventricle and atrium (no penetration) using micromanipulators
(Narishige) and Inchworm step motors (Burleigh), viewed under
a Nikon microscope (SMZ600). The micropipettes were filled with
MicroFil (P85, World Precision Instruments) in 3 M potassium
acetate solution (Sigma) and coloured with methylene blue (Sigma)
to easier visualise the tips during recordings. A chloridised silver
wire which carried the electrical signal to the amplifier was
inserted into the micropipettes and a second reference electrode
placed in the surrounding medium during recordings. The
differential amplifier (NPI electronics) used for recording was
operated in DC mode with the high pass filter set at 0.1 Hz. The
raw ECG signals were digitised (PowerLab; ADI Instruments) and
viewed using LabChart 7 (ADI Instruments).
Non-invasive recordings were taken by applying slight pressure
over the surface of the heart using the tip of a glass capillary.
Invasive recordings were taken by increasing the speed and also
the distance moved by the step motor to puncture the skin over the
heart. All of the recording equipment was housed on an air table
within a grounded Faraday cage to minimise background noise.
Experiments were performed at room temperature (21uC) except
when otherwise stated. Temperature was controlled using a sensor
placed in the recording plate and a homemade heating element
(Cryocon 24 temperature controller). For optimisation experi-
ments, recordings were taken for 5 mins. For the temperature
experiments, embryos were initially acclimatised to each temper-
ature for 30 mins before taking a recording of 5 mins. For drug
treatments, ECG recordings were taken continuously after drug
addition. A 5 mins segment before drug addition and a 15 minute
segment where QT prolongation was first apparent by visual
observation were selected for analysis. Recording lengths varied
ECG in Zebrafish Larvae
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depending on concentration of drug used, e.g. for terfenadine
treatment at 0.1, 0.3 and 1 mM recordings were taken for up to 1
hour or more, and for terfenadine at 50 mM recordings were taken
for 40 minutes.
Drug preparation
Cromakalim (a KATP channel opener [30]) and verapamil (an
anti-arrhythmic [31]) were obtained from Tocris Bioscience.
Haloperidol (a butyrophenone anti-psychotic [32]), terfenadine (a
histamine H1 receptor antagonist [33]) and tubocurarine (a
skeletal muscle relaxing alkaloid [34]) were obtained from Sigma
Aldrich. All drug stocks were made using either DMSO or distilled
water depending on solubility, then diluted using E3 embryo
medium to make up the final concentrations for recording
purposes with DMSO levels at 1%. ECG recordings were taken
for 5 mins in 3 ml of embryo medium before addition of drug
directly to the recording plate (1 ml) to produce the desired
concentration by undergoing a 1 in 4 dilution.
ECG data analysis
Analysis of the digitised ECG signal was carried out using
LabChart and the mean intervals for the ECG parameters R-R,
QRS, QT and QTc were calculated. For drug treatments the
percentage change in the corrected QT interval (QTc) before and
after drug administration was compared. One way ANOVA
analysis was then performed to determine statistical significance
between differences observed.
Z factor scores [35] were also calculated to determine the
robustness of the ECG system as a screening tool, using the mean
QTc percentage change before and after drug treatment for each
individual fish. The values before drug treatment were standar-
dised. The Z factor score was calculated using the following
equation: Z = 1– [36(sp+sn)/(mp - mn)],
where mp and sp represent mean and SD after treatment, while
mn and sn represent mean and SD before treatment. Z factor
scores fall into the following range: 1= ideal, 0.5–1= excellent, 0–
0.5 = marginal, ,0= poor. Z factor scores can never be more
than 1, and if the score is below 0 there is too much overlap
between the control and treatment groups to reliably make
a distinction. The temperature coefficient Q10 [36] was calculated
to determine the effect of temperature using the following
equation: Q10 = (R2–R1)
(10/T2–T1) where R1= heart rate at
temperature T1, R2= heart rate at temperature T2.
Results
ECG Signal Morphology and Reproducibility
The electrocardiogram represents summed electrical activity of
the heart and consists of three main components, which starts with
the small P wave (atrial depolarisation), the large QRS complex
(ventricular depolarisation) and ends with the T wave (ventricular
repolarisation) (Fig. 1A). To test the reliability of ECG measure-
ments with a glass electrode based setup, as described previously
[20], we used 3 dpf larvae as the heart is fully developed at this
stage and because they are easier to manipulate in terms of
positioning within wells of an agar plate following anaesthetisation,
as it was more difficult to position older fish due to development of
the swim bladder. After positioning of the electrode on the
boundary between the atrium and ventricle, LabChart software
was used to detect the ECG signal (Fig. 1B). Filtering steps were
introduced to remove background noise and obtain a signal
suitable for analysis (Fig. 1C) with distinctive P, QRS and T waves.
The signal was found to be stable (no change in waveform) over
the recording period (Fig. 1D), with all individual cycles being
close to the average over the whole recording period. Components
of the ECG waveform were analysed using the LabChart software,
the settings being first adjusted to detect R waves. This was done
by manually measuring the distance from one R wave to the next
and inputting this into the settings. After the R waves were
correctly identified the software could process the signal to
produce an averaged waveform and calculate interval durations
for different ECG components. Using this approach, measurement
of particular ECG parameters (e.g. QT interval) could be
performed automatically, allowing comparisons to be made
between individual fish and those exposed to different environ-
ments or drug treatments.
Detection of Effect of Motion Artefacts on ECG Signal
Although the above pilot experiments demonstrated reproduc-
ible detection of small amplitude P and T waves, there remained
the possibility of motion artefact (variations in isoelectric point
caused by heart movement). To check whether motion of the heart
or the body muscle could affect ECG signals we compared signals
recorded from the body surface over the heart using conditions
where motion artefacts were excluded, using two independent
analyses.
Firstly, recordings were performed with and without cromaka-
lim and secondly, comparing invasive (intracardial) and non-
invasive surface recordings. Cromakalim was added to the embryo
holding chamber and ECG signals were recorded before and after
drug exposure (QTc values shown in Table S1). As shown in
Fig. 2A cromakalim caused no perturbation to the QTc interval in
3 dpf zebrafish (n = 5 per concentration), but also did not reduce
contraction of cardiomyocytes at any of the tested concentrations.
Additionally, excitation-contraction uncouplers 2,3-butanedione-
monoxime (BDM) and blebbistatin were tested which were both
found to completely remove myocardial contractility and still
enable ECG signals to be recorded. However, both agents were
also found to have adverse effects on the ECG and embryo
survival (Fig. S1, S2 and S3, Movie S1). Therefore, as an
independent approach we compared ECG signals from invasive
and non-invasive electrode positioning. There was minimal
difference between recordings taken invasively and non-invasively
(n = 5; Fig. 2B, Table S2). Taken together, these results suggest
that surface ECG recordings are a true representation of the
electrical activity of the heart in 3 dpf zebrafish larvae.
We then investigated possible effects of various immobilising
agents. The commonly used anaesthetic MESAB [37] and the
paralytic agent tubocurarine [38] were tested. MESAB was
administered for 5–10 minutes before transfer of the fish to the
recording plate and tubocurarine was added to the recording plate
for continuous exposure. Both methods had no specific effect
(n = 10 per concentration) and produced comparable recordings
(Fig. 2C and 2D). At high concentrations (1 mg/ml) MESAB led
to increase of the R-R interval (P,0.05, see Table S3). Therefore,
for ECG recording purposes 0.3 mg/ml of MESAB was sub-
sequently used. With tubocurarine, immobilisation was only
effective if the embryo was continuously exposed, limiting its
suitability for treatment studies due to the possibility of drug
interactions.
Characterisation of ECG variables
To optimise the ECG recording method we assayed the effects
of varying parameters, which may influence heart function or
ECG detection. In poikilotherm fish species myocyte activity is
reduced at lower temperatures, which can both decrease QRS
amplitude and also lead to a reduction in heart rate (eH) as
a natural adaptive mechanism to aid survival during colder
ECG in Zebrafish Larvae
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climates or seasons [39]. At higher temperatures, increased eH
facilitates greater cardiac output to support a higher metabolic
activity/demand for oxygen consistent with normal biological rate
function. Thus, temperature is expected to have an effect on heart
rate and ECG measurements. Therefore, we tested the effect of
temperature between 18 to 28 Co in which range 3 dpf zebrafish
larvae develop normally. Increasing ambient temperature led to
increased mean heart rate and consequently decreased R-R, QT
and QTc intervals (Fig. 3A, Table S4) demonstrating expected
thermal sensitivity of heart function (n= 10, all P,0.05),
confirmed by calculated Q10 coefficients of 2.7 over the 10uC
range (Table S5).
Next we checked the developmental stages where reliable ECG
signal could be detected (Fig. 3B). Reproducible ECGs could be
recorded from zebrafish as early as long pec stage (2 dpf). ECG
recordings taken from larvae at different stages (n = 8 per stage)
showed differences in QT intervals when compared between 2 and
3, 2 and 4 and 2 and 5 dpf (all P,0.05), but not between 3 days
and older (Table S6). Differences were seen in the QTc interval
only between 2 and 5 dpf (P,0.05), while R-R intervals did not
differ among age groups. Therefore, embryos over 2 days of age
were used in subsequent experiments. For drug treatments, 3 dpf
(protruding mouth stage) were chosen due to easier manipulation
in wells of the recording plate (for reasons given above) and
because they can start swallowing at this stage, aiding drug uptake.
Differences in electrode placement in adult zebrafish ECGs was
thought to be the cause of variation in T wave morphology and
amplitude between different fish [2] [19]. For initial experiments,
the electrode was always positioned on the atrium-ventricle
boundary (see Fig. S4), as it was thought not to cause disturbance
to cardiac ion channels [20]. To determine whether positioning of
the electrode over the surface of the heart would impact on ECG
measurement in larvae (n = 10), 8 different positions along the
heart axis were tested (Fig. 4A and 4B, Table S7).
Movement of the positive electrode over the 5 dpf zebrafish
heart by 10 microns longitudinally influenced the ECG waveform,
particularly the amplitude (n = 3). However, the R-R, QT and
QTc intervals did not change significantly (Fig. 4C and 4D, Table
S8). Thus, electrode position was not critical for reliable ECG
measurement, as the waveform morphology and component
duration were unaffected.
Detection of changes in ion channel function
Next we asked whether the ECG method developed on pre-
feeding stage larvae could be used to detect the effect of QT
prolonging drugs, and demonstrate its suitability for analysing
cardiac dysfunction.
Figure 1. Detection of electrocardiographic signal. A) Depiction of an electrocardiogram and associated components, created using Adobe
Photoshop CS6, B) 2 second section of a raw ECG recording from a larval zebrafish (3 dpf) without digital filtering, C) digitally filtered version of the
ECG recording using low pass filtering to reduce background noise and produce a waveform suitable for analysis, D) analysed trace showing
waveform reproducibility and stability during the recording period, with each line representing one cardiac cycle. The dark line in the middle
represents the mean of all cycles from a 1 minute record.
doi:10.1371/journal.pone.0060552.g001
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Several compounds can predispose to cardiac tachycardia due
to QT prolonging effects caused by hERG channel blockade [40],
the main cardiac ion channel involved in ventricular repolarisa-
tion. Haloperidol binds hERG channels more potently than other
cardiac potassium channels, whereas terfenadine also has the
potential to block other ion channels [33]. Quantitative compar-
Figure 2. Exclusion of motion artefact and signal contamination. A) Mean ECG interval measurements obtained from 3 dpf larvae following
motion artefact exclusion using cromakalim drug treatment (n = 5 per concentration), B) parallel invasive and non-invasive recordings (n = 4), C) prior
MESAB anaesthesia for 5–10 minutes (n = 10 per concentration), and D) continuous tubocurarine exposure (n = 10 per concentration). Abbreviations:
RR = time between the peak of one QRS complex to the next, QT = time of ventricular depolarisation and repolarisation, QTc = QT corrected for heart
rate.
doi:10.1371/journal.pone.0060552.g002
Figure 3. Optimisation of ECG recording system. A) Mean ECG interval measurements obtained from 3 dpf larvae following exposure to
different ambient temperatures (n = 10), and B) over different developmental periods (2, 3, 4 and 5 days; n = 8).
doi:10.1371/journal.pone.0060552.g003
ECG in Zebrafish Larvae
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ison of the ECG waveform before and during terfenadine
treatment revealed an increase in the QTc interval in a concen-
tration-dependent manner (n = 8 per concentration, P,0.05;
Fig. 5A, Table S9). Apparent QT prolongation was observed
with widening of the T wave (see Fig. S5). QT prolongation with
haloperidol has been previously reported in adult zebrafish [2]. In
contrast to terfenadine, haloperidol led to an apparent QT
prolongation, which was found to be similar at various concentra-
tions (n = 8 per concentration, P,0.05; Fig. 5B, Table S10). This
was also seen with pimozide (n = 8 per concentration, Fig. S6,
Table S11). Verapamil (Fig. 5C), a known hERG blocker in vitro
also increased the QTc interval (n = 8 per concentration, P,0.05;
Fig. 5E, Table S12). Penicillin treatment was used as a negative
control as it has been shown not to cause QT prolongation in adult
zebrafish [2], and it was found to have no effect on the QTc
interval in zebrafish larvae (n = 8 per concentration, Fig. 5D,
Table S13), confirming high specificity of our system to detect
compounds that have an apparent QT prolonging effect. Taken
together, our results are in general agreement with those obtained
in adult zebrafish and human studies [2], confirming the drug
specificity for apparent QT prolongation in zebrafish larvae.
Additionally, with terfenadine the development of an arrhyth-
mia was also observed, which was time and concentration-
dependent causing marked alterations to the waveform (see Fig.
S7). Terfenadine, haloperidol and pimozide also induced an
atrioventricular (AV) block at particular concentrations and
exposure times (Movies S2, S3 and S4). Thus, the ECG
measurement system is also able to detect changes other than
QT prolongation, making it useful as a readout for other
cardiotoxic conditions.
Finally, we asked if the ECG detection system was suitable as
a drug toxicity screening tool. Therefore we calculated Z-factor
scores of reproducibility in repeat experiments [41] (Table 1). Z-
factor scores for terfenadine at 30 and 50 mM were calculated as
0.68 and 0.78 respectively, which fall into the excellent range
(.0.5). Additionally, for controls (e.g. low drug concentration,
solvent or no drug) the Z-factor was well outside the range (,0).
For verapamil at 25 mM, penicillin at 25 mM, no drug control and
DMSO solvent control the Z factors were 6.75, 26.56, 26.67–
2.71, respectively. These results demonstrate that the ECG
measurement system is sensitive in reproducibly detecting changes
caused by high concentrations of QT prolonging drugs as
compared to various controls and argue for its utility as a drug
toxicity screening tool.
Discussion
Optimisation of ECG Recording
We have optimised the parameters of an ECG recording system
to measure electrocardiograms from zebrafish embryos and larvae
(ranging from 2 to 5 days), using a similar technique to that
previously developed for 5 dpf embryos [20]. Compared to earlier
studies, where ECG recordings detected only P and R waves, with
our system all components of the ECG could be observed. In adult
Figure 4. Investigation of effect of electrode position on ECG waveform. A) Mean ECG interval measurements obtained from 3 dpf larvae at
different electrode positions over the heart (n = 10 per position), B) diagram of a 3 dpf larva with numbers identifying the different measurement
positions; image created using Adobe Photoshop CS6, C) 1) 2 second raw ECG recording and 2) 2 second raw ECG recording from a 5 dpf larva after
moving positive electrode 10 mm forward longitudinally, D) comparison of QTc intervals measured from 5 dpf larvae (n = 3) at starting position
(atrium/ventricle boundary) and after movement of electrode longitudinally by 5 mm and 10 mm. Key: 1 = sinus venosus, 2 = between atrium and
sinus venosus, 3 = base of atrium, 4 = apex of atrium, 5 = between atrium and ventricle, 6 = base of ventricle, 7 = apex of ventricle and 8 = bulbus
arteriosus.
doi:10.1371/journal.pone.0060552.g004
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zebrafish, the primary pacemaking site originates at the sinus
venosus-atrial junction and propagates from there during atrial
diastole into the ventricle [29]. In 3 dpf zebrafish the primary
pacemaking site is situated in the dorsal right quadrant of the
sinoatrial ring [42]. The pacemaker site is identified by a molecular
marker islet-1, whose expression is required for pacemaker activity
[43]. Hence, as early as 2 dpf all the elements required to generate
compound action potentials and effective cardiac conduction are
present, enabling the measurement of electrocardiograms.
When optimising the ECG recording procedure, tubocurarine
was only found to be effective as a sedating agent if added to the
recording plate directly, so that embryos were continuously
exposed. However, it did not affect eH at any of the tested
concentrations, whereas MESAB induced bradycardia at very
high concentrations. To eliminate motion artefacts, cromakalim
treatment was tested as it has been previously used as an
excitation-contraction uncoupler [44], causing membrane hyper-
polarisation. However, in zebrafish embryos it had no effect on the
ECG or heart contractility, which agrees with other studies [9].
Additionally, BDM and blebbistatin were also tested; both were
found to block myocardial contractility, as previously documented
[45], but also had adverse effects on the ECG signals that were
recorded and embryo survival. Therefore, to counteract these
limitations we also used intracardial ECG recording to demon-
strate there was no difference between invasive and non-invasive
recordings, and hence the latter could be used for assessing drug
treatments.
Figure 5. Effect of QT prolonging drugs on ECG measurements. A) Mean percentage change in QTc interval durations in 3 dpf larvae
following treatment with terfenadine (n = 10 per concentration), B) verapamil (n = 10 per concentration), C) haloperidol (n = 10 per concentration)
and D) penicillin (n = 10 per concentration). E) A raw ECG recording of a 3 dpf zebrafish before and 1 hour after treatment with 1 mM verapamil.
doi:10.1371/journal.pone.0060552.g005
Table 1. Z-factor scores for different treatment regimes.
Treatment Mean Z-factor score
Terfenadine 0.1 mM 21.671
Terfenadine 0.3 mM 20.254
Terfenadine 10 mM 20.371
Terfenadine 30 mM 0.676
Terfenadine 50 mM 0.784
Penicillin 25 mM 26.562
Verapamil 25 mM 26.747
DMSO (0.1%) 22.708
No drug 26.673
doi:10.1371/journal.pone.0060552.t001
ECG in Zebrafish Larvae
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A zebrafish embryo model for QT prolongation
Terfenadine causes QT prolongation in adult zebrafish [2],
which we also demonstrate in zebrafish embryos. The mean QTc
duration was dose and time-dependent, with lower concentrations
giving smaller changes and requiring longer incubation times.
Additionally, the dose-response was broadly sigmoidal, similar to
an ECG study with astemizole in adult zebrafish [2]. Haloperidol
also caused QT prolongation in zebrafish embryos, although at
higher concentrations than terfenadine and the effect was not
dose-dependent. Changes in the ECG waveform following
exposure to both QT prolonging drugs were similar to those
observed in adult zebrafish, i.e. widening of the QRS complex and
T wave [2].
One surprising result was that verapamil also caused QT
prolongation, in contrast to the response in mammals [46], but
consistent with data obtained in in vitro hERG cell assays (e.g.
human embryonic kidney cells) [47] and Xenopus laevis oocytes
[48], where verapamil is a potent hERG blocker. Verapamil
specifically binds to the alpha 1 c subunit of the L-type calcium
channel, preventing it from opening and therefore reducing
myocardial contractility by decreasing calcium influx [14].
At concentrations above 1 mM verapamil caused A/V decou-
pling of the zebrafish ECG (data not shown), consistent with other
studies [9]. This is similar to the mammalian response where
verapamil injections may cause arrhythmias, a common side effect
of anti-arrhythmics in overdose conditions [49]. Cardiotoxicity
studies with zebrafish embryos to detect hERG blockade only
reported bradycardia following verapamil exposure [8], although
younger (48 hpf) embryos were used and the concentrations may
have been too low to detect any other effect. As blockade of the
IKs channel (other main potassium channel affecting cardiac
repolarisation) is also linked with prolongation of the QT interval
[50] and verapamil is an IKs channel inhibitor [51] this may have
contributed to the QT prolongation observed, as effective
concentrations were relatively high. However, further studies are
required to identify the exact mechanism of action of verapamil on
zebrafish cardiac ion channels.
A zebrafish embryo model for cardiotoxicity testing
An additional effect of terfenadine and haloperidol was a 2:1 AV
block that was consistent for each fish tested but dependent on
both dose and exposure time. This type of AV block displayed
many features similar to those seen in humans (Movies S2, S3, S4).
It is known that when zERG is inhibited, a 2:1 AV block is
observed [52], as seen in similar experiments with mammals [53].
Currently, there is no evidence for 2:1 AV block as a result of
blockage of other ion channels [8]. While in humans AV block
only occurs rarely, it occurs in newborns and neonates alongside
QT prolongation [52]. Similarly, in zebrafish embryos QT
prolongation occurred before, and in some cases alongside
2:1 AV block. Although in humans the QT prolonging drug
astemizole causes 2:1 AV block at very high concentrations, this
occurs at lower doses in zebrafish embryos [52], suggesting that
zERG is more sensitive than the hERG channel. Alternatively, the
zebrafish ventricle may rely more upon the IKr current for
repolarisation than the atrium and therefore is more vulnerable to
AV block and also arrhythmia development, which was also
observed with terfenadine characterised by ectopic beats and
irregularities in heart rhythm [52].
The zebrafish embryo/larva is an attractive model for studying
cardiotoxicity due to its similarity to humans in terms of cardiac
physiology, as well as its easy accessibility, fast reproduction, high
fecundity, short generation times compared to other animal
models and its contribution to the 3 Rs (replacement, refinement
and reduction) of animals in research. Currently, QT interval
measurements in other animals show very wide variation and the
effects seen are often small [52]. While the readouts currently
obtainable with zebrafish (bradycardia, QT prolongation, 2:1 AV
block, arrhythmias) may be good surrogates for cardiac dysfunc-
tion in humans [52], zebrafish embryos may be more sensitive to
QT prolongation drugs compared to mammalian systems. It could
therefore be useful to test the QT-prolonging potential of drugs
currently under development using ECG technology that is non-
invasive, utilises live animals and is robust enough to use as
a screening tool based on calculated z factor scores which show
that the system is able to differentiate between natural variation
within samples and specific changes caused by drugs.
Although much recent research effort has focused on developing
high throughput assays to assess QT prolonging compounds using
transgenic zebrafish [8], the information that can be obtained
from ECG measurements is more insightful, as it can provide
detail of electrophysiological dynamics such as the possible
mechanisms underlying arrhythmogenesis. Besides compound
screening, the zebrafish embryo ECG system also offers the
opportunity to study cardiac mutants and associated pathologies.
The feasibility of mutagenesis screens allowed identification of
a variety of cardiac-specific mutants affecting both heart de-
velopment and physiology [54] [55]. One major drawback with
using zebrafish for compound screening is that drug penetration
and metabolism can be unpredictable. For example, it was
recently found that in zebrafish larvae terfenadine is almost
completely metabolised to azacyclone and terfenadine alcohol
[56], while in humans fexofenadine is predominantly formed. This
suggests that drug metabolism in zebrafish may utilise a different
pathway. On the other hand, metabolites of verapamil were
identified in zebrafish larvae that were the same as those produced
in humans [56]. Therefore, additional studies in this area would be
necessary to further validate the zebrafish as an additional animal
model for preclinical testing in cardiotoxicity screens [28].
Supporting Information
Figure S1 Exclusion of motion artefact with BDM. Screenshots
from a 3 dpf larval zebrafish ECG recording before (A) and after 2
minutes (B) of treatment with 15 mM BDM.
(TIF)
Figure S2 Effect on QTc with excitation-contraction uncoupler
BDM. Mean QTc interval durations of 3 dpf zebrafish larvae
before and after 2 minutes of treatment with 15 mM BDM
(n= 10, P.0.05).
(TIF)
Figure S3 Effect on QTc with excitation-contraction uncoupler
blebbistatin. Mean QTc interval durations of 3 dpf zebrafish
larvae before and after 10 minutes of treatment with 15 mM
blebbistatin (n = 5, P,0.05).
(TIF)
Figure S4 Electrode positioning for ECG recording. Depiction
of a 2 mM electrode tip positioned on the heart of a 60 hpf
zebrafish embryo to illustrate the relative sizes.
(TIF)
Figure S5 QT prolongation with terfenadine. Processed wave-
form showing QT prolongation with 50 mM terfenadine in a 3 dpf
larva: A) Averaged ECG waveform (red line) before drug
administration, B) T wave shift to the right observed after 1
minute of terfenadine treatment, C) more pronounced QT
prolongation after 7 minutes.
(TIF)
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Figure S6 QT prolongation with pimozide. The QT prolonging
drug pimozide was found to cause a statistically significant increase
in the corrected QT interval in 3 dpf zebrafish (n = 8, P,0.05).
(TIF)
Figure S7 Development of arrhythmia with terfenadine. ECG
screenshot of : A) 3 dpf zebrafish larva before treatment and B)
after 40 minutes of treatment with 50 mM terfenadine showing an
arrhythmic phenotype with the presence of ectopic beats.
(TIF)
Table S1 Effect of cromakalim on QTc interval duration.
(DOCX)
Table S2 Measured ECG intervals from invasive and non-
invasive recordings.
(DOCX)
Table S3 Measured ECG intervals following MESAB and
tubocurarine treatments.
(DOCX)
Table S4 Effect of temperature on ECG intervals.
(DOCX)
Table S5 Calculated Q10 coefficients for different temperature
ranges.
(DOCX)
Table S6 ECG intervals measured at different stages.
(DOCX)
Table S7 Measured QTc intervals at different positions on the
heart.
(DOCX)
Table S8 Measured QTc intervals following movement of
electrode.
(DOCX)
Table S9 Effect of terfenadine on QTc interval duration.
(DOCX)
Table S10 Effect of haloperidol on QTc interval duration.
(DOCX)
Table S11 Effect of pimozide on QTc interval duration.
(DOCX)
Table S12 Effect of verapamil on QTc interval duration.
(DOCX)
Table S13 Effect of penicillin on QTc interval duration.
(DOCX)
Movie S1 Reduction of myocardial contractility with blebbista-
tin. 3 dpf zebrafish larva before and after 20 minutes of treatment
with 15 mM blebbistatin.
(WMV)
Movie S2 AV block with terfenadine. 3 dpf zebrafish larva
before and after 30 minutes of treatment with 50 mM terfenadine.
(WMV)
Movie S3 AV block with haloperidol. 3 dpf zebrafish larva
before and after 45 minutes of treatment with 50 mM haloperidol.
(WMV)
Movie S4 AV block with pimozide. 3 dpf zebrafish larva before
and after 20 minutes of treatment with 100 mM pimozide.
(WMV)
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